STORY SUMMARY
Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
This is a brief summary of reporting from CBS News Health. Read the original for the full article and context.